Compare Amgen, Inc. (AMGN) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vale SA — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while Vale SA trades at $14.37 (market cap $62.26B). The key difference: Amgen, Inc. is far larger — about 3.6× Vale SA's market cap, and Vale SA pays the higher dividend (8.12%). Which is the better fit depends on your goals.
| AMGN | VALE | |
|---|---|---|
Market Cap | $225.71B | $62.26B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $17.82 |
52-Week Low | $271.18 | $9.71 |
Enterprise Value | $269.02B | $78.50B |
Dividend Yield | 2.42% | 8.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
VALE trades at $14.71, showing minimal daily movement with a slight decline of 0.07%. The stock faces technical bearish signals from moving averages while fundamentals reveal mixed performance with declining net income margins from 42.85% in 2022 to 5.11% in 2026, despite recent revenue stabilization. Recent earnings misses in Q4 2025 and Q1-Q2 2026 highlight operational challenges, though the company maintains strong cash flow generation of $8.8 billion from operations in 2025.
VALE presents a cautious investment case with analyst consensus leaning neutral (51.35% hold) despite a $16.79 price target suggesting 14% upside. Key opportunities include copper segment growth and disciplined capital returns, while risks involve rising operational costs, earnings volatility, and governance concerns highlighted by recent board disputes. The stock's valuation at 29.42 P/E appears stretched given profitability declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
